NeoMed Innovation IV fund close

NeoMed Management has held a final closing of NeoMed Innovation IV LP, a Jersey-based healthcare and life sciences venture capital fund. The fund has raised €104m. Investors include fund-of-funds, institutional and private investors based in the UK, Sweden, Norway, Saudi Arabia and Switzerland.

Erik Amble, founding partner of NeoMed Management, said: “We are pleased that NeoMed Innovation IV has reached its target size of €100m in a busy private equity fund raising environment in 2005. NeoMed is now well positioned as a leading European based venture capital firm specializing in the healthcare and life sciences industry.”

NeoMed invests in emerging healthcare and life sciences companies in Continental Europe, Scandinavia and to a lesser extent in the UK and the US. From offices in Oslo and Geneva, NeoMed acts as a lead or co-lead investor in companies located along the axis from Scandinavia to Switzerland.

NeoMed Innovation IV has recently completed due diligence and made its first investment in Endosense SA, a Swiss medical instrument company. Endosense is developing pressure guided catheters for the treatment of atrial fibrillation. The investment is made in syndication with 3i.

NeoMed Management has raised four specialized healthcare and life science investment funds: NeoMed I, formed in 1997 to invest in private and public companies; NeoMed II, a 1998 vintage venture capital fund; NeoMed III, a 2001 vintage venture capital fund and now NeoMed IV.